[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BRPI0607684A2 - composição farmacêutica, método para prevenir ou tratar distúrbios de depressão ou ansiedade, e, uso de (s)-n-[2-(1,6,7,8-tetraidro-2h-indeno[5,4-b]furan-8-il)-eti l]-propionamida - Google Patents

composição farmacêutica, método para prevenir ou tratar distúrbios de depressão ou ansiedade, e, uso de (s)-n-[2-(1,6,7,8-tetraidro-2h-indeno[5,4-b]furan-8-il)-eti l]-propionamida

Info

Publication number
BRPI0607684A2
BRPI0607684A2 BRPI0607684-0A BRPI0607684A BRPI0607684A2 BR PI0607684 A2 BRPI0607684 A2 BR PI0607684A2 BR PI0607684 A BRPI0607684 A BR PI0607684A BR PI0607684 A2 BRPI0607684 A2 BR PI0607684A2
Authority
BR
Brazil
Prior art keywords
indene
furan
propionamide
tetrahydro
ethyl
Prior art date
Application number
BRPI0607684-0A
Other languages
English (en)
Inventor
Keisuke Hirai
Masaomi Miyamoto
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37073564&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0607684(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of BRPI0607684A2 publication Critical patent/BRPI0607684A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Furan Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

COMPOSIçãO FARMACêUTICA, METODO PARA PREVENIR OU TRATAR DISTúRBIOS DE DEPRESSãO OU ANSIEDADE, E, USO DE (S)-N-[2-( 1 ,6,7,8-TETRAIDRO-2H-INDENO[5,4-B]FURAN-8-IL)-ETIL]-PROPI ONAMIDA. A presente invenção proporciona um agente profilático ou farmacêutico para distúrbios de depressão ou ansiedade, compreendendo (5)- N- [2-( 1 ,6,7,8-tetraidro-2H-indeno [5 ,4-b] furan-8-il)-etil] -propionamida.
BRPI0607684-0A 2005-04-04 2006-04-03 composição farmacêutica, método para prevenir ou tratar distúrbios de depressão ou ansiedade, e, uso de (s)-n-[2-(1,6,7,8-tetraidro-2h-indeno[5,4-b]furan-8-il)-eti l]-propionamida BRPI0607684A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2005107674 2005-04-04
PCT/JP2006/307047 WO2006107019A1 (ja) 2005-04-04 2006-04-03 うつ病または不安神経症の予防または治療剤

Publications (1)

Publication Number Publication Date
BRPI0607684A2 true BRPI0607684A2 (pt) 2009-09-22

Family

ID=37073564

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0607684-0A BRPI0607684A2 (pt) 2005-04-04 2006-04-03 composição farmacêutica, método para prevenir ou tratar distúrbios de depressão ou ansiedade, e, uso de (s)-n-[2-(1,6,7,8-tetraidro-2h-indeno[5,4-b]furan-8-il)-eti l]-propionamida

Country Status (23)

Country Link
US (1) US20090042861A1 (pt)
EP (1) EP1867641A4 (pt)
JP (1) JP5259181B2 (pt)
KR (1) KR20070118103A (pt)
CN (1) CN101189219A (pt)
AR (1) AR054435A1 (pt)
AU (1) AU2006231752B2 (pt)
BR (1) BRPI0607684A2 (pt)
CA (1) CA2602267A1 (pt)
CL (1) CL2009000980A1 (pt)
CR (1) CR9385A (pt)
GE (1) GEP20105001B (pt)
IL (1) IL186049A0 (pt)
MA (1) MA29677B1 (pt)
MY (1) MY142214A (pt)
NO (1) NO20075599L (pt)
NZ (1) NZ561677A (pt)
PE (1) PE20061355A1 (pt)
RU (1) RU2413510C2 (pt)
TW (1) TWI391132B (pt)
UA (1) UA89397C2 (pt)
WO (1) WO2006107019A1 (pt)
ZA (1) ZA200708445B (pt)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018176109A1 (pt) 2017-03-30 2018-10-04 Penello Temporao Jose Eduardo Composição mulivítamínica para aprimoramento da fluência verbal, dimimuição dos sintomas da ansiedade de performance e seu método de preparação

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101983193B (zh) * 2008-01-31 2014-03-12 武田药品工业株式会社 注意缺陷/多动障碍的预防或治疗剂
US8426461B2 (en) 2011-01-17 2013-04-23 Takeda Pharmaceutical Company Limited Orally dispersible tablet
WO2012099260A1 (en) * 2011-01-17 2012-07-26 Takeda Pharmaceutical Company Limited Orally dispersible tablet
EP2765985A1 (en) * 2011-10-14 2014-08-20 Takeda Pharmaceutical Company Limited Orally dispersible tablet
CN102718675B (zh) * 2012-06-07 2015-03-25 上海右手医药科技开发有限公司 阿戈美拉汀甲磺酸复合物及其制备方法
RU2571546C1 (ru) * 2014-07-14 2015-12-20 Государственное бюджетное образовательное учреждение высшего профессионального образования "Воронежский государственный медицинский университет имени Н.Н. Бурденко" Министерства здравоохранения Российской Федерации Способ дифференцированной диагностики и терапии синдрома ночной еды
CN108451917A (zh) * 2018-03-22 2018-08-28 仁和堂药业有限公司 高稳定性米安色林制剂的制备方法
CN113908165A (zh) 2020-07-10 2022-01-11 上海日馨医药科技股份有限公司 一种药物组合物及其应用
WO2025018810A1 (ko) * 2023-07-18 2025-01-23 주식회사 지오비스타 동물에 대한 정신질환 또는 행동장애의 예방 또는 치료용 조성물

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4241013A1 (de) * 1992-12-05 1994-06-09 Boehringer Ingelheim Kg Verwendung von 2-Amino-6-n-propyl-amino-4,5,6,7-tetrahydrobenzothiazol als Arzneimittel mit antidepressiver Wirkung
CA2192480C (en) * 1994-06-10 2007-07-24 Wai Ngor Chan Benzopyrans and their use as therapeutic agents
US5780470A (en) * 1995-06-02 1998-07-14 Bristol-Myers Squibb Company Melatonergic indanyl piperazines
CN100441574C (zh) * 1996-03-08 2008-12-10 武田药品工业株式会社 三环化合物及其制备和用途
JP2884153B2 (ja) * 1996-03-08 1999-04-19 武田薬品工業株式会社 三環性化合物、その製造法および剤
US6034239A (en) * 1996-03-08 2000-03-07 Takeda Chemical Industries, Ltd. Tricyclic compounds, their production and use
CN1206996C (zh) * 1998-06-09 2005-06-22 武田药品工业株式会社 用于治疗或预防睡眠障碍的药物组合物
JP3509637B2 (ja) * 1998-06-09 2004-03-22 武田薬品工業株式会社 睡眠障害予防治療剤
NZ523800A (en) * 2000-06-27 2005-02-25 Taisho Pharmaceutical Co Ltd Therapeutic preparation comprising a melanocortin receptor (MC4) antagonist or a piperazine derivative thereof for treating anxiety neurosis or depression
US6589978B2 (en) * 2000-06-30 2003-07-08 Hoffman-La Roche Inc. 1-sulfonyl pyrrolidine derivatives
US6569887B2 (en) * 2001-08-24 2003-05-27 Dov Pharmaceuticals Inc. (−)-1-(3,4-Dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake
EP1425017A1 (en) * 2001-09-13 2004-06-09 Schering Corporation Combination of an adenosine a2a receptor antagonist and an antidepressant or anxiolytic
US20070088079A1 (en) * 2005-09-20 2007-04-19 Takeda Pharmaceutical Company Limited Prophylactic or therapeutic agent for sleep disorder

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018176109A1 (pt) 2017-03-30 2018-10-04 Penello Temporao Jose Eduardo Composição mulivítamínica para aprimoramento da fluência verbal, dimimuição dos sintomas da ansiedade de performance e seu método de preparação

Also Published As

Publication number Publication date
AU2006231752A1 (en) 2006-10-12
US20090042861A1 (en) 2009-02-12
EP1867641A1 (en) 2007-12-19
MA29677B1 (fr) 2008-08-01
CR9385A (es) 2007-12-07
WO2006107019A1 (ja) 2006-10-12
AU2006231752B2 (en) 2012-03-01
GEP20105001B (en) 2010-06-10
RU2413510C2 (ru) 2011-03-10
CA2602267A1 (en) 2006-10-12
CN101189219A (zh) 2008-05-28
RU2007140986A (ru) 2009-05-20
NO20075599L (no) 2007-12-19
PE20061355A1 (es) 2007-01-15
JPWO2006107019A1 (ja) 2008-09-25
KR20070118103A (ko) 2007-12-13
UA89397C2 (ru) 2010-01-25
EP1867641A4 (en) 2010-01-13
AR054435A1 (es) 2007-06-27
NZ561677A (en) 2011-02-25
TW200719885A (en) 2007-06-01
CL2009000980A1 (es) 2009-08-14
JP5259181B2 (ja) 2013-08-07
TWI391132B (zh) 2013-04-01
MY142214A (en) 2010-11-15
IL186049A0 (en) 2008-02-09
ZA200708445B (en) 2009-03-25

Similar Documents

Publication Publication Date Title
BRPI0607684A2 (pt) composição farmacêutica, método para prevenir ou tratar distúrbios de depressão ou ansiedade, e, uso de (s)-n-[2-(1,6,7,8-tetraidro-2h-indeno[5,4-b]furan-8-il)-eti l]-propionamida
BRPI0717219A2 (pt) "composição imunogênica, método para tratar ou prevenir doença, e, uso de uma composição imunogênica."
BRPI0519047A2 (pt) mÉtodo para a produÇço de um agente de contraste marcador ou agente terapÊutico marcador, agentes de contraste marcadores e uso de agentes de contraste marcadores ou de agentes terapÊuticos marcadores
WO2004047830A3 (de) Pharmazeutische zusammensetzung aus einem beta-3-adrenozeptor-agonisten und einem serotonin- und/oder norepinephrin-reuptake-inhibitor deren verwendung zur behandlung von blasenfunktionsstörungen
BR0116370A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada por hppar em um paciente.
MY148459A (en) Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression
CL2007002384A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento de la psoriasis.
EA200601746A1 (ru) Применение ротиготина для лечения и предупреждения синдрома "паркинсонизм-плюс"
BRPI0718469A2 (pt) Uso de um antagonista de interleucina 1 (il-1), método para tratar, inibir, ou melhorar pseudogota, uso de um ou mais agentes terapêuticos, e, produto.
BRPI0508051A (pt) derivados de heteroarilaminopirazol utilizáveis para o tratamento de diabetes
NO20035025L (no) Anvendelse av osteopontin for behandling og/eller for a hindre nevrologiske sykdommer, samt farmasoytisk sammensetning omfattende osteopontin eller en antagonist med osteopontinaktivitet.
CL2007000789A1 (es) Compuestos derivados de malonamida, inhibidores de la gamma-secretasa; proceso de preparacion; composicion farmaceutica; y su uso en el tratamiento de la enfermedad de alzheimer.
BR0316723A (pt) Derivados de anilinopirazol úteis para o tratamento de diabetes
BRPI0612005A2 (pt) agente profilático ou terapêutico, composição oftalmológica, uso de selenoproteína p, e, método de prevenção/tratamento de uma doença corneal/conjuntival
ATE459353T1 (de) Gaboxadol zur behandlung von depressionen und anderen affektiven störungen
BRPI0408491A (pt) tratamento da doença de alzheimer
BR0210650A (pt) Tablete, e, uso do mesmo
BR0201524A (pt) Tratamento de combinação para ansiedade e depressão
BRPI0408889A (pt) uso de clusterina para o tratamento e/ou prevenção de doenças neurológicas periféricas
RS50148B (sr) Upotreba docetaksela za lečenje hepatoćelijskog karcinoma
WO2006034296A3 (en) Amino-containing compounds which inhibit memapsin 2 beta-secretase activity and methods of use thereof
GT200800066A (es) Derivados de 9-cloro-15-deoxiprostaglandina, procedimiento para su preparacion y su uso como medicamento.
NO20033318L (no) 2H-1-benzopyranderivater, fremgangsmåte ved fremstilling samt farmasöytiskesammensetninger derav
MX2009003974A (es) N-(2-hidroxietil)-n-metil-4-(quinolin-8-il(1-(tiazol-4-ilmetil)pi peridin-4-ilideno)metil)benzamida, el proceso para su sintesis, asi como su uso para el tratamiento del dolor, la ansiedad y la depresion.
BRPI0411174A (pt) combinação do modafinil analéptico e um antidepressivo para o tratamento da depressão

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2307 DE 24/03/2015.